FDMT completed randomization in its second pivotal wet AMD trial, began a Phase 3 DME trial, and reported lasting results from earlier trials. Its $375 million in cash is expected to fund its plan into the second half of 2028, but major Phase 3 results are still ahead.
That cash gives 4DMT room to run its trials without an immediate need for more funding. Earlier 2-year results showed lasting effects and fewer treatments. The larger Phase 3 trials still need to confirm those results.
Follow 4D Molecular Therapeutics, Inc. (FDMT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for FDMT